Current GBG research results presented at the DGS Congress 2026
As part of the poster sessions, new findings from two clinically highly relevant breast cancer research projects were presented.
Prof. Dr. Christiane Matuschek presented the first safety analysis of the NeoRad trial (GBG116). This randomized Phase III study investigates, in a total of 1,826 patients with invasive breast cancer, whether preoperative radiotherapy can be safely used as an alternative to the established postoperative irradiation approach. The first interim analysis focused on postoperative wound healing complications. The currently available data showed no relevant safety signals and support the continued conduct of the trial.
A particular highlight was the award of the Poster Prize at DGS 2026 to PD Dr. Mattea Reinisch. The presented prospective substudy of the NSABP B-59/GBG-96-GeparDouze trial investigated, for the first time, the impact of immune checkpoint inhibition on ovarian function and fertility in young patients with early triple-negative breast cancer. The results suggest numerically higher rates of chemotherapy-induced ovarian insufficiency under additional atezolizumab treatment. Although these differences were not statistically significant, the findings underline the importance of further research into fertility preservation and long-term effects of modern immunotherapies.
Both studies highlight the importance of translational and patient-centered research for the continued development of individualized treatment strategies in breast cancer.
